Concerning HSD17B13 and TM6SF2, the lack of an impact on the AIH course and ALT levels in our cohort confirms the available data from Germany and Poland, where no influence of both variants on clinical endpoints, laboratory values, or non-invasive fibrosis scores were observed [19,20]. This evidence concerns the gene GPT and autoimmune hepatitis.